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Abstract
Background: Elucidating the exact relationship between gene copy number and expression would enable
identification of regulatory mechanisms of abnormal gene expression and biological pathways of regulation. Most
current approaches either depend on linear correlation or on nonparametric tests of association that are insensitive
to the exact shape of the relationship. Based on knowledge of enzyme kinetics and gene regulation, we would
expect the functional shape of the relationship to be gene dependent and to be related to the gene regulatory
mechanisms involved. Here, we propose a statistical approach to investigate and distinguish between linear and
nonlinear dependences between DNA copy number alteration and mRNA expression.
Results: We applied the proposed method to DNA copy numbers derived from Illumina 109 K SNP-CGH arrays (using
the log R values) and expression data from Agilent 44 K mRNA arrays, focusing on commonly aberrated genomic loci in
a collection of 102 breast tumors. Regression analysis was used to identify the type of relationship (linear or nonlinear),
and subsequent pathway analysis revealed that genes displaying a linear relationship were overall associated with
substantially different biological processes than genes displaying a nonlinear relationship. In the group of genes with a
linear relationship, we found significant association to canonical pathways, including purine and pyrimidine metabolism
(for both deletions and amplifications) as well as estrogen metabolism (linear amplification) and BRCA-related response
to damage (linear deletion). In the group of genes displaying a nonlinear relationship, the top canonical pathways were
specific pathways like PTEN and PI13K/AKT (nonlinear amplification) and Wnt(B) and IL-2 signalling (nonlinear deletion).
Both amplifications and deletions pointed to the same affected pathways and identified cancer as the top significant
disease and cell cycle, cell signaling and cellular development as significant networks.
Conclusions: This paper presents a novel approach to assessing the validity of the dependence of expression data
on copy number data, and this approach may help in identifying the drivers of carcinogenesis.
Background
Cancer development and progression are complex pro-
cesses involving a series of genetic and functional abnorm-
alities. Joint analysis of array comparative genomic
hybridization (aCGH) copy number data and microarray
gene expression data may uncover biological relationships
relevant to our understanding of cancer. Previous
whole-genome analyses of copy number and gene
expression have led to the identification of global cellular
processes underlying malignant transformation and pro-
gression. In addition to basic biological applications, clini-
cal challenges such as early diagnosis, risk stratification,
and treatment failure [1-3] have been addressed. Combin-
ing large-scale data from a variety of analyses of tumors at
the DNA, RNA and protein levels has resulted in novel
areas of research directed toward better defining the mole-
cular basis of malignancy [4,5].
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gene expression alterations correlate with chromosomal
abnormalities. An early study of Hyman et al. [6] on
breast cancer cell lines using aCGH reported that 44%
of the highly amplified genes were over-expressed and
10.5% of the highly over-expressed genes were amplified.
These genes include known oncogenes and potential
therapeutic targets. Another early aCGH study on breast
cancers [7] found that 62% of the highly amplified genes
showed moderately or highly elevated expression. DNA
copy number was found to influence gene expression
a c r o s saw i d er a n g eo fD N Ac o p yn u m b e ra l t e r a t i o n s
(deletion and low-, mid- and high-level amplification),
and a two-fold change in DNA copy number lead on
t h ea v e r a g et oa1 . 5 - f o l dc h a n g ei nt h em R N Al e v e l .
Overall, at least 12% of all variation in gene expression
among breast tumors was directly attributed to variation
in gene copy number. Permutation analysis identified
genes whose expression was systematically attributable
to gene amplification. Several other association studies
also consider a linear correlation structure [8-10]. Van
Wieringer et al. [11] developed a nonparametric test to
detect copy number induced differential gene expres-
sion, while Schäfer et at. [12] proposed a bivariate
assessment to find DNA regions of equally directed
abnormalities in copy number and gene expression.
A recent study of Turner et al. [13] on triple
negative breast cancers identified genes consistently
over-expressed when amplified. The above attempts to
quantify the amount of RNA that may result from an
aberrant DNA locus applied a linear regression to
model the dependence of the expression data on the
copy number data.
Given the fact that correlations between copy number
and expression are used to estimate drivers in carcino-
genesis [14] it is very important to assess the validity of
the chosen methods in establishing the form of such
dependences. Most methods employ linear regression,
but the biological reality is that this interaction is readily
derailed from linearity by a number of regulatory
mechanisms contributing to gene expression, such as
transcriptional activation, miRNA-driven regulation, and
DNA methylation, to mention a few. The possibility of a
nonlinear relationship between copy number alterations
and the expression of specific genes must therefore be
explored and related to the mechanism of deregulation
of gene expression in the tumor. We believe that the
identification of nonlinear relationships will enable us to
identify the regulatory mechanisms of abnormal mRNA
expressions of relevance in the cancer process. Nonli-
nearity may reflect biological pathways of regulation,
such as DNA methylation, histone modification and
micro RNA, as well as the presence of transcription
binding and miRNA target sites, enhancers and
insulators; the presence of these factors must surely
influence the relationship to mRNA expression beyond
copy number itself.
In mathematical terms, any smooth nonlinear function
can be approximated locally by a quadratic polynomial.
In line with this, we consider a model in which mRNA
expression is a quadratic function of copy number to
investigate the presence of nonlinearity. We classify
each locus according to whether the quadratic model
provides a worse, equal or better fit to the data than the
linear model. The genes for which the copy number/
mRNA associations were classified as being linear or
nonlinear were further analyzed by pathway analysis in
order to discuss their biological interaction and regula-
tory mechanisms. We apply the procedure to copy num-
ber data (llumina 109 K SNP array) and expression data
(Agilent 44 K expression array) from 102 breast carci-
noma samples.
Results and Discussions
Spearman correlation
As a preliminary investigation, we first calculated the
in-cis Spearman correlation between copy number and
expression for all 40 K genomic locations (see Method).
Significant positive and negative correlations after false
discovery rate (FDR) correction were detected, resulting
in about 16 K associated pairs (Figure 1). Specifically,
the number of significantly correlated pairs was 15,654
at FDR10%, 13,085 for FDR5% (Figure 1), and 9,294 for
FDR1%; the vast majority being positive correlation as
expected, since a deletion most likely would lead to a
decrease in mRNA expression and an amplification to
increased mRNA expression. Still, some negatively cor-
related loci were seen, which may simply indicate noise
or, on the other hand, deserve more detailed sequence
Figure 1 In-cis correlations between CGH an mRNA.N u m b e ro f
significant correlated parts were in about 13 K loci (FDR 5%).
Horizontal axis indicates chromosomes and vertical axis indicates
Spearman correlation values (significant positive (red), negative
(green) and uncorrelated (black)).
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elements or amplifications of negative regulators and
thus reflect feedback mechanisms.
Application of the linear and quadratic models
For 4,957 and 4,495 gene locations for Amp and Del,
respectively, we applied the proposed linear and quadra-
tic models introduced in the Methods section. The
numbers for a significant linear/quadratic relationship
are summarized in Figure 2. A significant linear term
according to model (1) was observed for 2,004 loci of
the amplified genes (Amp) and 1,350 loci for the deleted
genes (Del) based on FDR5%. A significant quadratic
term according to model (2) was observed in 412 loci
for Amp and 387 loci for Del. The overlapping parts
such as loci with both significant linear and quadratic
components were 263 for Amp and 215 for Del. These
were also counted as loci significantly identified by the
quadratic model. Genes identified by the quadratic
model were amplified genes such as NDRG1 and
ERBB2. Figure 3 displays the scatter plot of the data
(circles), the predictions (solid line) and the 95% confi-
dence intervals (dashed lines) by the non-linear model
for these genes. The coefficient for the quadratic term of
NDRG1 was negative, suggesting a mechanism for sup-
pressing expression despite amplification; on the other
hand, the positive coefficient for ERBB2 suggested the
existence of further enhancement of expression. Conse-
quently, the different shapes of non-linearity may suggest
different molecular mechanisms of up-regulation and
thus require further verification by functional studies.
Indeed, this type of analysis should be considered as only
indicating the chromosomal locations with copy number
alterations, that is, where additional regulatory influences
are most likely. Furthermore, this analysis can be
obscured by the fact that there is a large inter-individual
variation as a result of complex trans gene-gene regula-
tion events in each tumor [15]. For instance, for NDRG1
there is clearly a population of samples where a higher
amplification does not result in higher mRNA levels, but
another population where this is the case.
Accuracy for predictions identified by
linear/quadratic model
When trying to characterize the relation between copy
numbers and expression levels, we need to filter out the
Genomic locations
Amp: 4,957    Del: 4,495
H0:null vs
H1:linear significant
Amp: 2,004
Del: 1,350
H0:null vs
H1:quadratic significant
Amp: 412
Del: 387
# genomic locations that quadratic is better than linear by AIC 
362 for Amp (88% of 412)       341 for Del (94% of 362)
Figure 2 Identified genomic locations by linear/quadratic models.
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values: This cloud of data reduces the fit of any model,
since it contains uninteresting individual variability
attached to the vast majority of points. If we randomly
thinned the clouds, we would balance the data better
along their range and see relations more clearly. In
order to do this, we performed median regression. We
first divided the CGH data into five regions where a
region is defined by xij -1.0 in models (1) and (2) (see
Methods). Then we created box plots for each of these
5 regions to indicate the degree of dispersion of each
particular region. To the median of the data in each
region, we again applied the linear and quadratic regres-
sion models (Figure 4). Solid and dash-dotted lines indi-
cate the predictions by quadratic and linear models,
respectively.
The variances of the prediction error for linear and
quadratic models are 0.112 and 0.0281 for NDRG1,a n d
2.94 and 0.313 for ERBB2. Furthermore, AICs for the
linear and quadratic models are 9.25 and 4.33 for
Figure 3 Estimated predictions for NDRG1 and ERBB2 obtained by quadratic model. Scatter plots are on vertical axis for non-logarithmic
mRNA data vs. horizontal axis for non-logarithmic PCF logR. Estimated predictions and the 95% confidential interval are represented by solid
and dashed lines, respectively.
Figure 4 Box-plots for the observations of NDRG1 and ERBB2 and predictions by linear and quadratic models. The plots are illustrated
for six regions to indicate the degree of dispersion of each particular region. Solid and dash-dotted lines indicate the predications by linear and
quadratic models, respectively.
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Page 4 of 12NDRG1, and 25.6 and 16.4 for ERBB2, respectively.
These results show that the quadratic model was better
than the linear model.
The loci identified as significant by the T-test and par-
tial F-test were also significant from the viewpoint of
model selection, based on the AIC (see Additional file 1).
Finally, mRNA expression data involve multiple
probes per gene in many cases, which allows us to
check for consistency. In the gene lists identified as
quadratic relationship for Amp, we found multiple
probes with both negative and positive quadratic coeffi-
cients for several genes, such as SDCCAG8, CLDN11
and STAU2.
Scatter plots for top 10 linear/quadratic models
When we investigate the individual scatter plots for
CGH copy number vs. mRNA expression, we can
observe in many cases a large population of samples
with a relatively strong effect on the mRNA level. Even
though they are found significant through model evalua-
tion by AIC and statistical tests, some predictions of
linear and quadratic relationships, as illustrated, are
rather poor. As discussed above for the case of NDRG1,
there is clearly a population of samples where a higher
amplification does not result in higher mRNA levels,
and another population where this is clearly the case. A
multitude of hypotheses could explain this effect, for
example the higher mRNA levels may not be copy-num-
ber-dependent, i.e. the copy number plays a small role
here, or the copy number effect may be conditioned on
another variable, and such a variable would differ from
sample to sample. The scatter plots and the predictions
of the top 10 models for each of the following categories
are presented as follows: i) linear model with positive
(first five panels) and negative (latter five panels) linear
coefficients for Amp are shown in Additional file 2
Figure 2a; ii) linear model with positive and negative lin-
ear coefficients for Del - in Additional file 2 Figure 2b;
iii) quadratic model with positive and negative quadratic
coefficients for Amp - in Additional file 2 Figure 2c; and
iv) quadratic model with positive and negative quadratic
coefficients for Del - in Additional file 2 Figure 2d. The
top 10 models were selected through the following two
procedures: 1.We sorted p-values for the test statistics
(see Methods), and 2. From the lowest p-values of test
statistics, we selected the 5 lowest p-values of positive
and of negative linear/quadratic coefficients.
In Additional file 2 Figures 2c and 2d, we show both
linear and quadratic predictions by dotted and solid
lines, respectively. The genomic locations, estimated lin-
ear/quadratic coefficients, the p-values for the coeffi-
cients and statistics, likelihood and AIC for linear/
quadratic models are summarized in Additional file 3.
As we can see in Additional file 2 Figures 2a and 2b,
the scatter plots tend to distribute uniformly around the
predictions. On the other hand, in the case of the quad-
ratic model with positive quadratic coefficient (Addi-
tional file 2 Figure 2 c, first five panels, here called ‘case
1’), a few data are distributed in higher expression levels
of higher copy number regions. However, in the case of
the quadratic model with negative coefficient for Amp
(Additional file 2 Figure 2c, second five panels, called
‘case 2’), we see that many samples are distributed in
higher expression levels for normal copy regions, while
some samples are distributed in lower expression levels
for higher copy regions. Furthermore, in the case of the
quadratic model with positive coefficient for Del (Addi-
tional file 2 Figure 2d, first five panels, called ‘case 3’), a
few samples showed higher expression in the loss
region, and in the case of the quadratic model with
negative coefficient for Del (Additional file 2 Figure 2d,
second five panels, called ‘case 4’), many samples
showed higher expression in the normal copy region,
while a few samples showed lower expression in the loss
region. For the cases of ‘case 2’ and ‘case 4’, we can con-
struct two different models to describe the obtained
characteristics:1) Suppression of expression despite
amplification, and 2) The linear relationship of expres-
sion level to copy number variability.
Pathway analysis
To investigate the biological functional mechanisms,
pathway analysis was performed by Ingenuity Pathway
Analysis (IPA). We summarize the outputs for the asso-
ciated network functions, diseases and disorders, and
molecular and cellular functions in Table 1. The p-value
associated with a biological process or pathway annota-
tion is a measure of its statistical significance with
respect to the Functions/Pathways/Lists Eligible mole-
cules for the dataset and a Reference Set of molecules
(which define the molecules that could possibly have
been Functions/Pathways/Lists Eligible). The p-value
was calculated with the right-tailed Fisher’sE x a c tT e s t ,
and we applied the Benjamini-Hochberg [16] multiple-
testing p-value. The ratio of the canonical pathways is
calculated by dividing the number of molecules in a
given pathway that meet the cut-off criteria by the total
number of molecules that make up that pathway. Net-
works were scored based on the number of Network Eli-
gible molecules they contained. In Table 1 a score over
10 was recognized as a meaningfully higher score. The
network Score was based on the hypergeometric distri-
bution (Source: IPA online manual).
The genes with a linear relationship were involved in
significant canonical pathways, including purine and
pyrimidine metabolism (for both deletions and amplifi-
cations), as well as estrogen metabolism and ER signal-
ing (linear amplification) and response to damage (linear
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models Top Canonical Pathways -log(B_H p-value) Ratio
Linear
Amp
Estrogen receptor signaling 6.95e-01 15/135 (0.111)
Pyrimidine Metabolism 3.31e-01 15/151 (0.099)
Mitochondrial Dysfunction 3.31e-01 13/127 (0.102)
Molecular Mechanisms of Cancer 1.77e-01 25/359 (0.07)
Oxidative Phosphorylation 1.77-01 13/140 (0.093)
Linear
Del
Purine metabolism 1.1e00 23/303 (0.076)
DNA Methylation and Transcriptional Repression Signaling 5.24e-01 4/23 (0.174)
Reelin Signaling in Neurons 5.24e-01 8/82 (0.098)
Pyrimidine Metabolism 5.24e-01 12/151 (0.079)
Toll-like Receptor Signaling 5.24e-01 6/51 (0.118)
Quad
Amp
P13K/AKT signaling 1.93e00 9/132 (0.068)
Neuregulin signaling 1.49e00 7/98 (0.071)
PTEN signaling 4.97e-01 6/120 (0.05)
TR/RXR activation 2.95e-01 5/93 (0.054)
ERK5 Signaling 2.74e-01 4/67 (0.06)
Quad
Del
Cell cycle regulation by BTG family proteins 1.88e00 5/36 (0.139)
CTLA4 signaling in cytotoxic T lymphocytes 1.83e00 7/98 (0.071)
Ceramide signaling 1.48e00 6/85 (0.071)
Wnt/ß-catenin signaling 6.97e-01 7/173 (0.04)
IL-2 signaling 6.97e-01 4/59 (0.068)
models Top Associated Network Functions Score
Linear
Amp
Embryonic Development, Tissue Development, DNA Replication, Recombination, and Repair 41
Dermatological Diseases and Conditions, Genetic Disorder, Metabolic Disease 35
Cell Signaling, RNA Post-Transcriptional Modification, Gene Expression 35
Gene Expression, Cellular Compromise, Cardiovascular System Development and Function 35
Cellular Development, Carbohydrate Metabolism, Lipid Metabolism 33
Linear
Del
Cellular assembly and organization, Cellular function and maintenance, DNA replication, Recombination, and Repair 37
RNA Post-Transcriptional Modification, Gene Expression, Immunological Disease 37
Embryonic Development, Cell Morphology, Cellular Development 37
Gene Expression, Cell Cycle, Cellular Development 33
Cellular Movement, Nervous System Development and Function, Cellular Assembly and Organization 27
Quad
Amp
Molecular Transport, Small Molecule Biochemistry, Cell Cycle 44
Gene Expression, Cancer, Gastrointestinal Disease 41
Cell Morphology, Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization 26
Gene Expression, Endocrine System Disorders, Genetic Disorder 21
Gene Expression, Connective Tissue Disorders, Immunological Disease 19
Quad
Del
Cell Cycle, Carbohydrate Metabolism, Lipid Metabolism 45
Organismal Injury and Abnormalities, Cellular Development, Cell Death 23
Post-Translational Modification, Protein Degradation, Protein Synthesis 21
Cellular Assembly and Organization, Nervous System Development and Function, Cell-To-Cell Signaling and Interact 21
Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking 19
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models Diseases and disorders B-H p-value # Molecules
Linear
Amp
Cancer 2.24e-05 - 4.45e-01 120
Reproductive system disease 2.24e-05 - 4.39e-01 86
Development disorder 6.55 e -02 - 4.39e-01 19
Inflammatory response 3.77e-01 - 4.39e-01 5
Genetic disorder 4.39e-01 - 4.39e-01 38
Linear
Del
Cancer 4,27e-06 - 2.4e-01 102
Reproductive system disease 4.27e-06 - 2.4e-01 75
Infectious disease 6.9e-03 - 2.4e-01 58
Infection mechanism 7.62e-03 - 2.4e-01 60
Dermatological Diseases and Conditions 9.78e-02 - 2.4e-01 28
Quad
Amp
Cancer 6.54e-03 - 1.68e-01 73
Reproductive system disease 6.54e-03 - 1.68e-01 34
Gastrointestinal disease 1.57e-01 - 1.68e-01 9
Hepatic system disease 1.57e-01 - 1.68e-01 8
Inflammatory disease 1.57e-01 - 1.68e-01 12
Quad
Del
Genetic disorder 1.54e-01 - 2.11e-01 33
Neurological disease 1.54e-01 - 2.11e-01 24
Psychological disorders 1.54e-01 - 2.11e-01 18
Cancer 1.54e-01 - 2.11e-01 15
Metabolic Disease 1.54e-01 - 2.11e-01 7
models Molecular and Cellular Functions B-H p-value # Molecules
Linear
Amp
Gene expression 5.23e-03 - 4.45e-01 133
Cell death 1.21e-01 - 4.45e-01 50
Cellular growth and proliferation 1.21e-01 - 4.39e-01 33
Molecular transport 3.77e-01 - 4.39e-01 52
Protein trafficking 3.77e-01 - 4.39e-01 24
Linear
Del
Cellular assembly and organization 1.47e-05 - 2.4e-01 75
Cellular function and maintenance 1.47e-05 - 2.4e-01 44
Cellular development 2.56e-02 - 2.4e-01 39
Cellular growth and proliferation 2.56e-02 - 2.4e-01 15
DNA replication, recombination, and repair 4.28e-02 - 2.4e-01 41
Quad
Amp
Cellular development 1.57e-01 - 1.68e-01 20
Cell death 1.57e-01 - 1.68e-01 25
Cell cycle 1.57e-01 - 1.68e-01 16
Cell morphology 1.57e-01 - 1.68e-01 24
Gene expression 1.57e-01 - 1.68e-01 23
Quad
Del
Post-translation modification 1.54e-01 - 2.11e-01 19
Cell morphology 1.54e-01 - 2.11e-01 13
Cellular development 1.54e-01 - 2.11e-01 14
Carbohydrate metabolism 1.54e-01 - 2.11e-01 9
Lipid metabolism 1.54e-01 - 2.11e-01 16
Canonical pathways, association network functions, disease and disorders and molecular and cellular functions were analyzed by IPA to assemble gene lists
identified by linear/quadratic models for Amp and Del.
Solvang et al. BMC Bioinformatics 2011, 12:197
http://www.biomedcentral.com/1471-2105/12/197
Page 7 of 12deletion). The top canonical pathways for the genes with
a quadratic relationship were specific pathways like
PTEN, Neuregulin signaling and PI13K/AKT (quadratic
amplification) as well as Wnt(B) and IL-2 signaling
(quadratic deletion). These pathways have been very
extensively studied and implied in breast cancer devel-
opment. Notably, the Neuregulin pathway, containing
the well-known breast cancer oncogene ERBB2, as well
as PTEN and P13K/AKT signaling, was found to be a
top pathway of deregulation of breast cancer at multiple
levels, including DNA methylation and alelle loss. These
results were obtained by a method called multiple con-
certed disruption (MCD) designed to identify genes
aberrated at different levels. This supports our hypoth-
esis that genes subjected to alterations in expression at
multiple levels will have stronger non-linear components
than genes that are merely “explained” by copy number.
All four categories identified cancer as the top signifi-
cant disease and cell cycle, cell signalling, and cellular
development as significant networks. The linear model
was more often seen with genes with overrepresentation
of molecular and cellular functions of gene expression,
cellular maintenance and synthesis, while genes with a
nonlinear relation had functions involving development
and lipid metabolism.
Investigation for genomic locations identified
by linear and quadratic models
The genomic localizations of the significant DNA aber-
rations/mRNA expression dependences, which were
found to be significant by the linear and quadratic mod-
els, were plotted on the line maps shown in Figure 5a
for Amp and Figure 5b for Del. The figures present
three maps: loci with linear term (top), loci with quadra-
tic term (middle), and the loci this study is restricted to
(bottom). The black lines in the maps indicate signifi-
cant genomic locations obtained by these models. The
vertical axis of the line maps (’positive’ and ‘negative’)
indicates whether the estimated coefficients for the lin-
ear and quadratic terms were positive or negative. These
plots show that in the case of amplification (Figure 5a),
the coefficients are more often positive in the loci with
linear relationships but more often negative in the case
of quadratic relationships. This indicates that negative
regulatory mechanisms of gene expression are better
explained by the quadratic model. In the case of dele-
tion (Figure 5b), however, the opposite is observed: The
relationships between DNA copy number and mRNA is
more often negative in the case of linearity and positive
in the case of quadratic interaction. This may indicate
‘suppression’ or feedback related to regulation. Interest-
ingly, non-linear relationships were hardly ever observed
on their own but mostly coincided with areas of linear
relationship between DNA aberrations and mRNA
expression. This finding suggests that 1) in order to
become non-linear, these aberrations first need to occur,
and 2) only parts of the amplicons are subjected to
further transcriptional enhancement/modulation, and
these peaks may point to refined target genes driving
clonal selection.
RT-PCR Validation
To address the concern that the deviation from linearity
observed here may be introduced by the different
dynamic range or other technical noise on the arrays
(CGH and mRNA expressions), we used TaqMan to
perform quantitative RT PCR analysis of the tumor
DNA and mRNA expressed from the ERBB2 locus
(Figure 6). The results confirmed a non-linear relationship.
Conclusions
The statistical analysis described in this paper allowed
us to distinguish linear and nonlinear dependences
between copy number alterations and mRNA expression
in-cis. We applied the procedure to 109 K logR data
(Illumina) and 44 K mRNA data (Agilent) for 102 breast
cancer samples and found a clear indication of deviation
from linearity. This seems reasonable to expect because
regulatory processes within a pathway are complex and
unlikely to be subordinated to linearity. Although the
linear model represents a first-order approximation of a
Taylor expansion (for example of the regression func-
tion), the quality of the approximation will vary. In loci
with strong nonlinearities, threshold effects and complex
local interactions by a non-linear model will fit data bet-
ter. However, it is difficult to draw the exact regression
curve for most genes due to noise in both SNP-CGH
and expression signals, in addition to inter-individual
variation between the tumors. Additional single-gene-
based assays will be necessary to confirm these trends
obtained from large-throughput, array-based experi-
ments. In order to explore the possibility of an even
more general nature of nonlinearity, we would apply
more flexible or non-parametric models rather than the
simple quadratic model. It is important to consider non-
linearity because CGH-mRNA correlations are used to
estimate drivers in carcinogenesis, making it is essential
to assess the validity of the chosen methods.
Methods
Study population
The study population consisted of 102 tumor samples
from patients with early stage breast cancer [17]. The 44
K mRNA expression data were obtained with the Agi-
lent platform and DNA copy number from 109 K SNP-
CGH logR values were obtained using an Illumina
aCGH as previously described [18]. Preprocessing of
mRNA data included imputation of missing values using
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Fig.5b
Figure 5 Line maps of genomic locations for the significant DNA aberrations/mRNA expression dependences. The line maps describe
genomic locations for the significant DNA aberrations/mRNA expression dependences found by linear (top) and quadratic (middle) for Amp (a)
and Del (b). The specific regions for Amp (a) and Del (b), which we detected in Methods, are illustrated in the bottom panels.
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Page 9 of 12LLS in the R library called ‘pcaMethod’ with k = 20.
Quantile normalization was applied by normalizeBetwee-
nArrays in the R library called limma. For the aCGH
data, every tumor genome was segmented by fitting a
piecewise constant function to the logR values using the
Piecewise Constant Fitting (PCF) algorithm [19,20]. This
algorithm produces an estimated copy number at every
genomic location, including all mRNA probe locations.
Accordingly, for every mRNA probe we found a corre-
sponding copy number value. In this manner, a com-
bined set of mRNA and logR values were obtained at
40,442 genomic locations for each of the 102 samples
(raw data can be accessed from http://www.ifi.uio.no/
bioinf/Projects/GenomeArchitecture).
Linear and nonlinear modelling and its evaluation
We describe the relationship between gene expression
and copy number by regression incis. Let yij and xij indi-
cate the non-logarithmic mRNA and PCF filtered copy
numbers for sample i and location j, respectively. We
first describe the linear model with i.i.d. Gaussian noise:
yij = αj + βj(xij − 1.0) + εij (1)
Note that for a copy number ratio of xij =1 . 0 ,t h e
gene expression equals the intercept aj.The parameter bj
quantifies the strength of the relationship between gene
expression and copy number at the jth genomic loca-
tion. Note that the interpretation of the sign of the para-
meter bj in models (1) and (2) will differ for Amp and
Del locations. For example, a positive bj in model (1)
will correspond to a positive linear relationship between
expression and copy number for Amp locations and a
negative relationship for Del locations.
Next, we introduce a quadratic nonlinear model repre-
sented by
yij = αj + βj(xij − 1.0) + γj(xij − 1.0)2 + εij. (2)
As for the previous model, the intercept denotes the
gene expression corresponding to normal DNA copy
number. Model (2) incorporates a quadratic term that
allows expression to depend nonlinearly on copy num-
ber. To investigate whether a linear model fits better
than the null model, we applied a t-test separately for
amplification and deletion (H0 : bj = 0 against H1: bj ≠
0). To investigate whether a quadratic model is better
than a linear model, we applied a partial F-test (H0 :gj =
0a g a i n s tH1: gj ≠ 0) separately for amplifications and
deletions. A false discovery rate [16] was applied to cor-
rect p-values for multiple testing. In order to directly
compare the model candidates, we used the Akaike
information criterion (AIC) [21]. The model which gave
the minimum AIC was defined to be the best AIC
model. Models (1) and (2) were fitted by robustfit
(Matlab
® The Mathworks http://www.mathworks.com/
products/matlab).
Categorization of genomic loci for model fitting
Since amplifications and deletions in copy number
aberrations may involve different regulatory mechan-
isms, these two events were analyzed independently.
We first split the 40,442 genomic locations into cate-
gories Amp, Del and Normal, corresponding to the
loci of frequent amplification, frequent deletion or
neither. The Amp category consists of all genomic
locations for which at least 20% of the samples had
PCF-filtered (see details in Methods section) logR
Figure 6 RT-PCR Validation. The left panel indicates ERBB2 data and quadratic predictions from array and the right panel indicates that the
plots and the quadratic prediction curve of the data are given for the DNA and mRNA tumor expressed from the ERBB2 locus for TaqMan
quantitative RT PCR analysis.
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Page 10 of 12values above 0.15, the Del category consists of all
genomic locations for which at least 20% of the PCF
filtered logR values were below -0.15, and all other
locations are assigned to the normal category. In the-
ory, a location could be assigned to both Amp and
Del; however, this never occurred in our data set using
the above thresholds. Numbers of Amp and Del loca-
tions were 4.957 and 4.495, respectively, as described
in Figure 7. For Amp locations, the linear and quadra-
tic models were fitted to the samples with normal copy
number and gain, and for Del locations the linear and
quadratic models were fitted to the samples with nor-
mal copy number and loss.
Secondly, we drew a histogram of all mean values, tak-
ing the PCF fitted values for each location. We identify
three peaks around the frequencies for -0.12, 0, and
0.15, and one small peak around 0.075. The central
component of this mixture, representing the norm,
seems to be located between -0.05 and +0.05: these sam-
ples were taken as part of both groups Amp and Del.
The analyses steps are summarized in Additional file 4
and the flow diagram of the testing procedure are
described in Additional file 5.
Pathway analyses
Pathway analysis was applied in order to investigate the
biological functional interaction for the lists of genes
obtained by the above analysis, using a tool called Inge-
nuity Pathway Analysis (IPA, Ingenuity systems http://
www.ingenuity.com/). This delivers a rapid assessment
of the signalling and metabolic pathways, molecular net-
works, and biological processes that are most signifi-
cantly perturbed in the dataset of interest. IPA offers
many options for finding insights into relationships,
mechanisms, functions and pathway of relevance.
Additional material
Additional file 1: Supplementary Figure 1: Number of lower AIC vs
number of p-values. To assess the accuracy for the results identified by
the linear and quadratic models, we compared the results related to the
p-values obtained by T test and partial F test and model selection by
AIC. The p-values for loci identified significantly by the quadratic model
were sorted by small p-value. We calculated the top 200, 400, 600, 800,
1000 and 1811 for Amp and 200, 400, 600, 800, 1000 and 1226 for Del in
the case of the linear model, and the top 100, 200, 300, 400 and 412 loci
for Amp and 100, 200, 300 and 387 loci for Del in the case of the
quadratic model. For each group, we also calculated AICs for the cases
applying linear and quadratic models and counted the number of the
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Figure 7 Amp/Del genomic locations. The vertical axis indicates the percentages of the sample number with PCF filtered values > 0.15 (red)
and PCF filtered values < -0.15 (green) divided by the number of samples. The horizontal line at 20% indicates the threshold we used in this
analysis. The locations above the threshold line are defined as Amp (red, 12% of all) or Del (green, 11% of all) and were then investigated for
linear and nonlinear relationships, respectively.
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Page 11 of 12cases where AIC by the quadratic model was smaller than AIC by the
linear model. As can be seen in the Supplementary figures, the number
of p-values was close to the number of lower AICs in most cases,
indicating that the loci identified significantly by T-test and partial F-test
were also significant from the viewpoint of the model selection
approach based on the information criterion.
Additional file 2: Supplementary Figures 2a-d. The scatter plots and
the predictions of the top 10 models of each of the following categories:
i) linear model with positive (first five panels) and negative (latter five
panels) linear coefficients for Amp (a), ii) linear model with positive and
negative linear coefficients for Del (b), iii) quadratic model with positive
and negative quadratic coefficients for Amp (c), and iv) quadratic model
with positive and negative quadratic coefficients for Del (d). In these
figures, the black dots indicate each sample that shows normal and gain
(loss) regions where the model was applied, and the grey dots indicate
the rest of the samples, which were distinguished as loss (gain) regions.
Additional file 3: Estimated coefficients, p-values, log-likelihood and
AIC in top 10 linear and quadratic models corresponding to
Additional file 2 Supplementary Figure 2a-dare summarized.
Additional file 4: The analyses steps.
Additional file 5: Flow diagram of the testing procedure.
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